fcγr

The Anti-CD32 FcγRIIA Antibody (IV.3) is a chimeric mouse IgG2b antibody designed to target human CD32 FcγRIIA. The recommended isotype control for this antibody is Mouse IgG2b kappa, Isotype Control.

Rituximab is an anti-CD20 chimeric monoclonal antibody used to study certain autoimmune diseases and cancers.

Rozanolixizumab (RYSTIGGO) is a high-affinity humanized immunoglobulin G4 monoclonal antibody targeting Fc receptors (FcRn) in human newborns for the study of pathogenic IgG in autoimmune and alloimmune diseases.

Daratumumab is a human monoclonal antibody that targets CD38 a cell surface protein that is overexpressed on multiple myeloma MM) cells.

Alemtuzumab is a humanized monoclonal antibody against CD52 an antigen found on the surface of normal and malignant lymphocytes.

Obinutuzumab (Obinutuzumab afutuzumab) GA101) is a glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.

Ofatumumab is a fully human monoclonal antibody to CD20 which appears to inhibit early-stage B lymphocyte activation

Mupadolimab (CPI-006) is a humanized FC-γR binding deficient IgG1 anti-CD73 antibody with potential anticancer activity and activation of CD73POS B cells.

Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor designed as a decoy or scavenger to target Fc and FcγR, binding and neutralizing pathogenic IgG. Its utility lies in mitigating autoimmune diseases, with a particular focus on systemic lupus erythematosus (SLE) research [1].